IP Library Granted Patent US 7,923,454
Granted Patent B2
US 7,923,454 · App. 10/936,431 · Granted Apr 12, 2011

Opioid and opioid-like compounds and uses thereof

Assignee: Jenken Biosciences, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,923,454
App. No.
10/936,431
Granted
Apr 12, 2011
Kind
B2
Abstract

The present invention relates to opioid and opioid-like compounds, and pharmaceutical formulations containing the same and methods of use thereof. Uses of the present invention include, but are not limited to, use for the prevention and treatment of septic shock and other disorders. The compounds described herein can be water soluble and can act through mechanisms mediated through pathways other than opiate receptors.

Claims (21)

1. A method of treating conditions selected from the group consisting of, organ damage selected from the group consisting of liver, lung and kidney damage, rheumatoid arthritis, Crohn's disease, and multiple sclerosis, comprising administering to a subject in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of a compound selected from the group consisting of dextromethorphan, 3-methoxy-morphinan and 3-hydroxy-morphinan, and enantiomers, diastereoisomers, and pharmaceutically acceptable salts thereof.

2. A method of treating conditions selected from the group consisting of, organ damage, selected from the group consisting of liver, lung and kidney damage, rheumatoid arthritis, Crohn's disease, and multiple sclerosis, comprising administering to a subject in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula R-A-X:

wherein,

R is methyl, hydroxy or alkoxy,

A has the following structure:

and

X is methyl, cyclobutyl, n-propyl, CN, or enantiomers, diastereoisomers, or pharmaceutically acceptable salts thereof.

3. The method of claim 1 , wherein the pharmaceutical composition is administered orally in an amount selected from 2 to 100 mg per unit dose and one to four times a day.

4. The method of claim 1 , wherein the pharmaceutical composition is administered parenterally in an amount selected from 2 to 100 mg per unit dose and one to four times a day.

5. The method of claim 1 , wherein the organ damage is liver damage.

6. The method of claim 1 , wherein the organ damage is lung damage.

7. The method of claim 1 , wherein the organ damage is kidney damage.

8. A method of treating conditions selected from the group consisting of inflammation, and inflammatory liver, lung or kidney damage comprising administering to a subject in need thereof, a pharmaceutical composition comprising a therapeutically effective amount, from a daily dose of 2 to 100 mg, of a compound of the formula: RAX wherein X is selected from the group consisting of hydrogen and alkyl, A is

and R is selected from the group consisting of hydroxy, alkyl and alkoxy.

9. A method according to claim 8 wherein the compound administered is 3-methyl-17-methyl morphinan.

10. A method according to claim 8 wherein the compound administered is 3-methoxymorphinan.

11. A method according to claim 8 wherein the compound administered is 3-hydroxymorphinan.

12. A method according to claim 8 wherein the condition being treated is inflammation.

13. A method according to claim 8 wherein the condition being treated is inflammatory liver damage.

14. A method according to claim 8 wherein the condition being treated is inflammatory kidney damage.

15. A method according to claim 8 wherein the condition being treated is inflammatory lung damage.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2014
From: JENKEN BIOSCIENCES, INC.
To: TAIWANJ PHARMACEUTICALS CO., LTD.
Reel/Frame 033749/0930 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2005
From: WU, EDWIN S.C.; YEN, MAO-HSIUNG; FAN, CHIN-TSAI
To: JENKEN BIOSCIENCES, INC.
Reel/Frame 016160/0460 →
Continuity (4)
Continuation In Part PCTUS0315461 · May 16, 2003
Provisional Application 60380841 · May 17, 2002
Provisional Application 60518448 · Nov 7, 2003
Related Publication 20050107415A1 · May 19, 2005